<p>维京治疗公司（NASDAQ:VKTX - 获取免费报告）于周三发布了季度财报。这家生物技术公司报告的季度每股收益为（$0.41），低于分析师一致预期的（$0.34），差距为（$0.07），据 Zacks 报道。</p>
<p>获取 <strong>维京治疗</strong> 的提醒：</p>
<h2>维京治疗股价上涨 1.4%</h2>
<ul>
<li>维京治疗股票上涨但难以保持涨幅</li>
</ul>
<p>周三，VKTX 的交易价格上涨了$0.36，达到$25.84。该公司交易了 4,145,398 股股票，而其平均交易量为 4,045,729 股。该股票的 50 日移动平均价格为$26.75，200 日移动平均价格为$41.30。维京治疗的 1 年最低价为$18.92，1 年最高价为$81.86。该公司的市值为 29 亿美元，市盈率为-25.84，贝塔值为 0.84。</p>
<h2>华尔街分析师观点</h2>
<p>VKTX 已成为多份研究分析报告的主题。HC Wainwright 在 4 月 17 日的研究报告中重申了 “买入” 评级，并设定了维京治疗股票的目标价为$102.00。高盛集团在 4 月 8 日的报告中开始覆盖维京治疗股票，给予 “中性” 评级，目标价为$30.00。B. Riley 在 2 月 7 日的报告中重申了 “买入” 评级，并将维京治疗股票的目标价从$109.00 下调至$96.00。加拿大丰业银行在 2 月 13 日的研究报告中开始覆盖维京治疗，设定了 “行业表现优于大盘” 评级和$102.00 的目标价。最后，Maxim Group 在 2 月 7 日的报告中将维京治疗股票的目标价从$120.00 下调至$70.00，并给予 “买入” 评级。一位分析师给予该股票 “卖出” 评级，两位分析师给予 “持有” 评级，十位分析师给予 “买入” 评级，一位分析师给予 “强烈买入” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为$89.75。</p>
<ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
<p><strong>获取我们对维京治疗的最新股票分析</strong></p>
<h2>维京治疗的内部活动</h2>
<p>在其他新闻中，董事 Sarah Kathryn Rouan 在 3 月 31 日的交易中购买了 1,240 股该公司的股票。每股购买价格为$24.15，总价值为$29,946.00。购买后，该董事现在直接拥有 1,240 股该公司的股票，价值约为$29,946。这代表了其持股的∞增长。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。4.70% 的股票由内部人士持有。</p>
<h2>关于维京治疗</h2>
<p>（获取免费报告）</p>
<ul>
<li>MarketBeat 周回顾 – 03/17 - 03/21</li>
</ul>
<p>维京治疗公司是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。该公司的主要药物候选者是 VK2809，一种口服可用的选择性甲状腺激素受体β（TRß）激动剂，目前正在进行 IIb 期临床试验，以治疗经活检确认的非酒精性脂肪性肝炎以及非酒精性脂肪肝病（NAFLD）。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比维京治疗更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>IBM 的第一季度收益能否引发股票的突破？</li>
<li>什么是低市盈率，它对投资者有什么启示？</li>
<li>标普 500 和纳斯达克 100 出现死亡交叉——你应该担心吗？</li>
<li>哪里可以找到财报电话会议的记录</li>
<li>基本面良好，这五只股票却被抛售</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在维京治疗吗？</h2>
<p>在考虑维京治疗之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而维京治疗并不在名单上。</p>
<p>虽然维京治疗目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Viking治疗

<p>Viking Therapeutics（纳斯达克代码：VKTX）报告的季度每股收益为（$0.41），低于预期$0.07。该股上涨 1.4%，报$25.84，市值为 29 亿美元。分析师的评级不一，普遍评级为 “适度买入”，目标价为$89.75。内部交易方面，董事 Sarah Kathryn Rouan 购买了 1,240 股。该公司专注于开发代谢疾病的治疗方案，其主要候选药物 VK2809 正在进行 IIb 期临床试验</p>

<p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07), Zacks reports.</p>
<div class="lb-trans"><p>维京治疗公司（NASDAQ:VKTX - 获取免费报告）于周三发布了季度财报。这家生物技术公司报告的季度每股收益为（$0.41），低于分析师一致预期的（$0.34），差距为（$0.07），据 Zacks 报道。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>维京治疗</strong> 的提醒：</p>
</div><h2>Viking Therapeutics Trading Up 1.4 %</h2>
<div class="lb-trans"><h2>维京治疗股价上涨 1.4%</h2>
</div><ul>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>维京治疗股票上涨但难以保持涨幅</li>
</ul>
</div><p>VKTX traded up $0.36 during trading on Wednesday, hitting $25.84. 4,145,398 shares of the company's stock were exchanged, compared to its average volume of 4,045,729. The stock has a 50 day moving average price of $26.75 and a 200 day moving average price of $41.30. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86. The firm has a market cap of $2.90 billion, a P/E ratio of -25.84 and a beta of 0.84.</p>
<div class="lb-trans"><p>周三，VKTX 的交易价格上涨了$0.36，达到$25.84。该公司交易了 4,145,398 股股票，而其平均交易量为 4,045,729 股。该股票的 50 日移动平均价格为$26.75，200 日移动平均价格为$41.30。维京治疗的 1 年最低价为$18.92，1 年最高价为$81.86。该公司的市值为 29 亿美元，市盈率为-25.84，贝塔值为 0.84。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>VKTX has been the topic of a number of research analyst reports. HC Wainwright reiterated a &#34;buy&#34; rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Thursday, April 17th. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a &#34;neutral&#34; rating and a $30.00 price target on the stock. B. Riley reiterated a &#34;buy&#34; rating and set a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Scotiabank began coverage on Viking Therapeutics in a research note on Thursday, February 13th. They set a &#34;sector outperform&#34; rating and a $102.00 price objective on the stock. Finally, Maxim Group reduced their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $89.75.</p>
<div class="lb-trans"><p>VKTX 已成为多份研究分析报告的主题。HC Wainwright 在 4 月 17 日的研究报告中重申了 “买入” 评级，并设定了维京治疗股票的目标价为$102.00。高盛集团在 4 月 8 日的报告中开始覆盖维京治疗股票，给予 “中性” 评级，目标价为$30.00。B. Riley 在 2 月 7 日的报告中重申了 “买入” 评级，并将维京治疗股票的目标价从$109.00 下调至$96.00。加拿大丰业银行在 2 月 13 日的研究报告中开始覆盖维京治疗，设定了 “行业表现优于大盘” 评级和$102.00 的目标价。最后，Maxim Group 在 2 月 7 日的报告中将维京治疗股票的目标价从$120.00 下调至$70.00，并给予 “买入” 评级。一位分析师给予该股票 “卖出” 评级，两位分析师给予 “持有” 评级，十位分析师给予 “买入” 评级，一位分析师给予 “强烈买入” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为$89.75。</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Viking Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对维京治疗的最新股票分析</strong></p>
</div><h2>Insider Activity at Viking Therapeutics</h2>
<div class="lb-trans"><h2>维京治疗的内部活动</h2>
</div><p>In other news, Director Sarah Kathryn Rouan purchased 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.70% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Sarah Kathryn Rouan 在 3 月 31 日的交易中购买了 1,240 股该公司的股票。每股购买价格为$24.15，总价值为$29,946.00。购买后，该董事现在直接拥有 1,240 股该公司的股票，价值约为$29,946。这代表了其持股的∞增长。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。4.70% 的股票由内部人士持有。</p>
</div><h2>About Viking Therapeutics</h2>
<div class="lb-trans"><h2>关于维京治疗</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>MarketBeat Week in Review – 03/17 - 03/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 03/17 - 03/21</li>
</ul>
</div><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p>
<div class="lb-trans"><p>维京治疗公司是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。该公司的主要药物候选者是 VK2809，一种口服可用的选择性甲状腺激素受体β（TRß）激动剂，目前正在进行 IIb 期临床试验，以治疗经活检确认的非酒精性脂肪性肝炎以及非酒精性脂肪肝病（NAFLD）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Viking Therapeutics</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Can IBM’s Q1 Earnings Spark a Breakout for the Stock?</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>S&amp;P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Fundamentally Sound, These 5 Stocks Sold Off Anyway</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比维京治疗更好</li>
<li>便士股票适合你的投资组合吗？</li>
<li>IBM 的第一季度收益能否引发股票的突破？</li>
<li>什么是低市盈率，它对投资者有什么启示？</li>
<li>标普 500 和纳斯达克 100 出现死亡交叉——你应该担心吗？</li>
<li>哪里可以找到财报电话会议的记录</li>
<li>基本面良好，这五只股票却被抛售</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在维京治疗吗？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑维京治疗之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而维京治疗并不在名单上。</p>
</div><p>While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然维京治疗目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Viking 治疗（NASDAQ 代码：VKTX）公布了收益结果，每股收益比预期低 0.07 美元